Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Biomarkers in Colorectal Cancer Chemoprevention
NCT03957902Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2019
- Primary completion
- May 2025
- Countries
- 1
- Sponsor
- IIS Aragón
- Modality
- Orthosteric Ligands
- Drugs
- aspirin
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, randomised, open-label trial of aspirin in colorectal cancer (CRC), sponsored by IIS Aragón. Primary endpoint: Acetylation of Cyclooxygenase Enzymes at 3 weeks. Started May 2019; status: recruiting.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients aged 18-79 with newly diagnosed colorectal cancer, excluding those with prior NSAID use, bleeding disorders, or history of peptic ulcers.
04
Endpoints
Primary
Acetylation of Cyclooxygenase Enzymes
Beyond the preview
Go deeper on NCT03957902.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957902.